Prosecution Insights
Last updated: April 19, 2026
Application No. 18/903,801

REGENERATIVE PEPTIDES AND METHODS FOR USE THEREOF

Final Rejection §112
Filed
Oct 01, 2024
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Animate Biosciences, Inc.
OA Round
4 (Final)
61%
Grant Probability
Moderate
5-6
OA Rounds
2y 11m
To Grant
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
436 granted / 719 resolved
+0.6% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
61 currently pending
Career history
780
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 719 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim Status Claims 49 and 59-80 are pending. Claims 59-80 have been added. Claims 15, 17, 22, 24-25, 31, 33, 35, 38, 41-48 and 50-58 have been canceled. Claims 49 and 59-80 are being examined in this application. Claim Objections Claims 60-62, 68-71 and 76 are objected to because of the following informalities: Claims 60-62 and 68-71 should be rewritten to recite “…amino acid residues in length”. Claim 76 should be rewritten to recite “…localized scleroderma . Appropriate correction is required. Claim Rejections - 35 USC § 112 The rejection of claims 15, 17, 22, 24-25, 31, 33, 35, 38 and 41-48 under 35 USC 112(a) is withdrawn in view of the amendments to the claims. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 62 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 62 is drawn to the method of claim 49, wherein the at least one peptide is about 51 to about 100 amino acids in length. The specification does not define the term “about”. It is noted that the propriety of the use of the expression "about" in claims to permit "of some tolerance" is established by long practice in the Patent Office. See W.L. Gore & Associates, Inc. v. Garlock, Inc., 82 U.S.P.Q. (BNA) 303, 306 (Fed. Cir. 1983) and Ex Parte King, 82 U.S.P.Q. (BNA) 450, 451 (Pat. & Trademark Office Bd. App. 1948). The term "about" allows for some tolerance in the ranges disclosed. In In re Ayers, the Federal Circuit held that "at least about 10%" was anticipated by a reference that disclosed "about 8%" because the term "about" allowed for some tolerance. In re Ayers, 154 F.2d 182, 185 (Fed. Cir. 1946). Similarly, in Johnson and Johnson v. W.L. Gore & Associates, Inc., the Court allowed for "about 1.2" to be inclusive of 1.0. See Johnson and Johnson,436 F.Supp. 704, 728-729 (Fed. Cir. 1977). Although about has never been confined to specific percentage of variability, the Johnson and Johnson decision at least implies that 16% variability is permissible when "about" is used (1.0/1.2 = ~16.6% variability). Thus, the term about implicitly discloses some variability even though the specification may not literally cite this variability. Accordingly, "about 100 amino acids in length" encompasses 116 amino acids, which is broader than the subject matter of claim 49 (“not more than 100 amino acid residues in length”). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 49,59,63-67,72-75 and 77-80 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Oct 01, 2024
Application Filed
Feb 23, 2025
Non-Final Rejection — §112
May 23, 2025
Response Filed
Jun 05, 2025
Final Rejection — §112
Sep 08, 2025
Request for Continued Examination
Sep 10, 2025
Response after Non-Final Action
Nov 30, 2025
Non-Final Rejection — §112
Mar 03, 2026
Response Filed
Mar 17, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595283
POLYPEPTIDE TAG AND APPLICATION THEREOF IN IN VITRO PROTEIN SYNTHESIS
2y 5m to grant Granted Apr 07, 2026
Patent 12590119
PEPTIDE SYNTHESIS AND SYSTEM THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12582924
METHODS FOR OBTAINING LIQUID FROM A SOLID PHASE
2y 5m to grant Granted Mar 24, 2026
Patent 12569574
PROTEINS WITH CARDIOPROTECTIVE ACTIVITY
2y 5m to grant Granted Mar 10, 2026
Patent 12569435
Ocular Compositions and Methods Thereof
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+33.6%)
2y 11m
Median Time to Grant
High
PTA Risk
Based on 719 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month